Dubai Health, GE HealthCare to enhance Point-of-Care Ultrasound education, practice in MENA region
The collaboration combines Dubai Health's academic and innovation expertise with GE HealthCare's advanced technological capabilities to enhance medical education, strengthen clinical decision-making, and improve health outcomes throughout the UAE and the broader MENA region.
The MoU will establish Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU) as a POCUS Education Center of Excellence and a pioneer in Point-of-Care Ultrasound education across the MENA region.
Key initiatives include: a 'Train-of-Trainer (TOT)' structured program to build capacity in certified facilitators and trainers. The Facilitator Training Program will also enhance the scalability and effectiveness of POCUS programme delivery and execution across a broader geographical region, enabling wider participation of attendees, students, and delegates.
In addition, the collaboration will extend to the co-development of AI solutions through Dubai Health Innovations, which supports transformative solutions that enhance patient care, drive medical advancements, and improve health outcomes.
This partnership will focus on the development and validation of emerging AI technologies in areas of mutual interest, such as radiology and computer vision, aiming to improve diagnostic accuracy, streamline clinical workflows, and facilitate early detection of medical conditions. Through this joint effort, both parties seek to foster innovation, accelerate adoption of cutting-edge AI tools, and contribute to the advancement of healthcare delivery in the region.
Dr. Hanan Al Suwaidi, Acting Chief Academic Officer of Dubai Health and Provost of MBRU said, 'This collaboration reflects Dubai Health's commitment to delivering on our 'Patient First' promise through the integration of care, learning, and innovation to elevate healthcare standards. By building capacity in POCUS education and co-developing AI-powered solutions, we are empowering clinicians with next-generation technologies to improve patient outcomes.'
President of GE HealthCare EAGM (Eurasian and African Growth Markets), Konstantinos Deligiannis, said, 'This MoU marks a pivotal moment for POCUS advancement in the MENA region. We are excited to partner with Dubai Health to build skills, accelerate knowledge transfer, and strengthen the local and regional healthcare expertise. By combining our advanced ultrasound technology with innovative AI solutions, we are committed to enhancing diagnostic accuracy and efficiency, ultimately contributing to the region's broader healthcare objectives.'
Dr. Rasha Buhumaid, Vice Dean of Graduate Medical Education, Assistant Professor of Emergency Medicine, and Programme Director of POCUS at MBRU, further commented, 'This partnership is a significant step toward realising our vision of positioning MBRU as a Centre of Excellence for Point-of-Care Ultrasound education. Through the Facilitator Training Programme and other initiatives, this collaboration enables us to strengthen the integration of POCUS into clinical practice, build sustainable expertise, and support better outcomes at the point of care and across the health system.'
Professor Nabil Zary, Senior Director of the Institute of Learning at Dubai Health, also noted, 'Education is at the heart of sustainable healthcare transformation. This partnership with GE HealthCare enables us to deliver high-impact, evidence-based training in POCUS that not only equips clinicians with advanced skills but also fosters a culture of continuous learning and innovation.' The MoU between the two parties will be in effect for two years and is renewable by mutual agreement.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gulf Business
11 minutes ago
- Gulf Business
Hub71 startup, Ovasave, raises $1.2m pre-seed round
Image: Supplied Ovasave, an Abu Dhabi-based digital health startup focused on fertility and hormonal care, has raised $1.2m in pre-seed funding, a sign of growing investor appetite for women's health innovation across the Gulf. The funding round was led by PlusVC, Annex Investments, and New York-based venture studio 25 Madison. It also drew support from strategic angel investors and family offices across the UAE and Saudi Arabia, reflecting a widening pool of capital being deployed into early-stage femtech ventures. Backed by Abu Dhabi's The company plans to use the funding to accelerate its expansion across the GCC, build new corporate partnerships, and roll out the next phase of its mobile platform, which will offer menstrual cycle tracking, symptom monitoring, AI-guided treatment protocols, and access to care. Ovasave aiming to fill gap when it comes women's healthcare in the region 'There is a critical need for timely intervention in women's health, particularly around fertility and hormonal health,' said Torkia Mahloul, co-founder and CEO of Ovasave. 'This funding marks a crucial step in our mission to disrupt women's health and expand access across the region.' Majd Abu Zant, co-founder of The raise comes amid a push by Gulf governments to diversify healthcare offerings and advance gender equality through national policy. In the UAE, reforms in healthcare, technology, and women's rights have created a fertile ground for emerging FemTech players to gain traction. Femtech, once considered a niche sub-sector, is increasingly drawing investor interest. A recent report by FemTech Analytics projects the MENA femtech market will reach $3.8bn by 2031, growing at a compound annual rate of 15 percent. Startups like Ovasave are hoping to ride that wave by addressing long-standing taboos and gaps in care, particularly in fertility and hormonal health. The startup is now preparing to launch in Saudi Arabia later this summer, as part of a broader three-year regional growth strategy. By combining AI-powered tools with direct access to care, Ovasave aims to move women's health from reactive to proactive – a shift that investors are starting to bet on.
Gulf Business
11 minutes ago
- Gulf Business
Mubadala announces reinvestment in PCI Pharma Services
Image: Getty Images Mubadala Investment Company, the Abu Dhabi-based sovereign investor, said on Monday it has entered into an agreement to make a significant reinvestment in PCI Pharma Services, a global contract development and manufacturing organisation (CDMO) focused on biotherapies. The deal is part of a strategic transaction co-led by Bain Capital and existing lead investor Kohlberg. Partners Group will also remain involved with a minority investment, Mubadala said in a statement. Mubadala first invested in PCI has been expanding its presence in pharma Over the past five years, 'PCI Pharma Services has been one of our top-performing healthcare investments and is a testament to what can be achieved when long-term active investors partner with strong management teams,' said Camilla Languille, co-CEO of Private Equity at Mubadala. 'Our team will continue to focus on similar opportunities in the healthcare space as the sustained outsourcing of mission-critical but non-core activities by pharma companies aligns with our commitment to address global unmet clinical needs, reduce the cost of care to the system, and enable greater access,' she added. Mubadala investment reflects PCI's potential Mina Hamoodi, head of Healthcare at Mubadala, said: 'Our reinvestment in PCI reflects our deep conviction in the company's mission, leadership, and long-term potential. At this important juncture, we are delighted to welcome Bain Capital, an industry-leading healthcare investor with deep expertise in growing pharma services businesses, as a partner.' She added that Mubadala looks forward to partnering with Bain and Kohlberg and working closely with PCI's management as the company enters its 'next chapter of accelerated growth'. The new investment will support both organic and inorganic expansion, including growth in sterile fill-finish injectables, high-potency drug manufacturing, and specialised therapies. The company also plans continued investment in the United States to strengthen domestic pharmaceutical manufacturing and supply chain resilience.
The National
41 minutes ago
- The National
What is meno-washing? What to look out for in products marketed for menopause
menopause is not one of the most joyous parts of a woman's life. Lasting up to 10 years – with four years the average – it typically begins in a woman's early fifties, but for some, it begins in their thirties or forties, with symptoms wide-ranging and difficult to pinpoint. Indicators include brain fog, hot flushes, night sweats, irregular menstruation, joint pain and thinning hair. And these days, a menopausal woman is likely to be bombarded with myriad products and services all promising to alleviate those symptoms – many with no scientific or medical evidence to back up their claims. Dubbed 'meno-washing', this relatively new trend has seen a boom in the number of products, often everyday items, which are being re-branded as menopausal aids. 'Women should be cautious because the menopause market has exploded with products promising quick fixes, often without robust evidence to back their claims,' says Sara Beattie, positive psychology practitioner and menopause coach. 'Many menopause-branded products fall into the unregulated supplement category, meaning they're not required to prove safety or effectiveness before being sold,' adds Sharon James, menopause coach and co-founder of the GCC Menopause Hub. 'Some brands have taken advantage of the growing awareness around menopause by slapping a 'menopause' label on everyday products, like skincare, snacks and drinks, and increasing the price. This kind of meno-washing plays on women's insecurities and the lack of access to reliable education or guidance.' Supplements and celebrities With a trend report from the Global Wellness Summit projecting the 'business of menopause' will hit $600 billion this year, celebrities have been quick to jump on the menopause bandwagon amid wider public conversations around the time of change in a woman's life. Actresses Naomi Watts and Judy Greer have both launched menopause products and solution companies, Stripes and Wile, respectively, while Halle Berry has co-created 'a three-month, structured menopause programme' through her lifestyle company, Re-spin. 'Given the wide range of products readily available that claim to be menopausal aids, it is natural for women to fall prey to fancy labels and unrealistic claims,' says Dr Mehnaz Abdulla, specialist obstetrics and gynaecology at Aster Clinic, Al Nahda. 'It is important to understand that products marketed as 'natural' or 'herbal' can also have side effects and are usually not studied for adverse effects, as they do not fall under standard pharmaceutical regulations.' She adds: 'Though some may have positive effects in relieving symptoms, it is always best to consult a doctor to determine which supplements are the most suitable and safest.' More research into the products and their side effects is essential, says James, who adds: 'We do need to better understand why we're taking them, what evidence exists behind their use, and whether they're appropriate for our individual health needs. Be aware of how long the trials and studies have been conducted on the product, and who has funded them.' Menopause and skincare Along with supplements, skincare is one of the biggest industries that has pivoted to marketing menopause-specific products. During perimenopause, oestrogen levels decrease, affecting the skin's moisture content, collagen and elasticity, which can lead to wrinkles, sagging and fine lines. It can also affect the skin's ability to heal as quickly. 'Some products that were originally marketed as anti-ageing are now being rebranded with menopause on the label,' says Beattie. 'But just because something targets ageing does not mean it addresses the specific hormonal changes linked to menopause, such as the effects of falling oestrogen on collagen, hydration, or skin barrier function. Anti-ageing and menopause skincare are not the same, and slapping menopause on a product does not turn it into a solution for hormonal changes.' How to avoid falling for meno-washing When it comes to products being marketed as menopause-specific, women are advised to watch out for items that claim to over-deliver and use vague words such as 'balance' or fear-based marketing to drive sales. 'It is virtually impossible for a single supplement or treatment to address all menopause symptoms effectively,' says Beattie. 'Menopause affects multiple systems in the body, hormonal, cognitive, emotional, cardiovascular, skeletal, so symptoms vary widely from person to person. Any product claiming to be a universal solution should raise red flags.' Doctors point out that lifestyle changes and hormone replacement therapy (HRT) are the most effective ways to manage the menopausal symptoms, but that each woman's needs are different. 'Menopause is not just a biological change, but an existential transition. Every woman has her own unique story,' says Dr Giuseppe Bellucci, expert in functional nutrition, metabolism, and longevity at Baldan. 'The strategy may involve a combination of tools such as targeted therapy, local remedies, diet, exercise, psychological support if needed, and supplements for individual symptoms. However, these should only be used if supported by studies validating their actual effectiveness.'
